profit from every $100 of sales.
$0$100
BeyondSpring
$0.62-1.44% today
-68.5% in 1 year
1-year low $0.431-year high $2.35
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What BeyondSpring sold, what it kept, and what it did with the cash.
Sales went from $1.35 million in 2022 to $0 in 2025, with -$1.01 million of profit last year.
SalesProfit
BeyondSpring vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| BeyondSpring | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads BeyondSpring's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 0 | 0 | 0 | |
| – | – | – | – | |
| -37 | -15 | -9 | -9 | |
| -36 | -15 | -8 | -9 | |
| -33 | -21 | -11 | -1 | |
| -0.85 | -0.54 | -0.28 | -0.02 | |
| – | – | – | – | |
| -2,756.4% | – | – | – | |
| -2,463.3% | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 46 | 25 | 34 | 26 |
| Cash | 34 | 5 | 3 | 8 |
| Total debt | 5 | 1 | 1 | 0 |
| Total liabilities | 49 | 48 | 49 | 50 |
| -6 | -27 | -33 | -32 | |
| 39 | 39 | 40 | 40 | |
| – | – | – | – | |
| 556.6% | 78.4% | 33.8% | 3.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -28 | -16 | -16 | -20 | |
| 0 | 0 | 0 | 0 | |
| -28 | -17 | -17 | -20 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 1 | 2 | 1 |
Valuation
- –
- 0.3×
- –
- -1.6×
- 18.8×
- –
- –
- -111.1%
- -131.2%
- 0.0%
Profitability
- 0.0%
- -2,756.4%
- -2,463.3%
- 0.0%
- -136.4%
- 639.5%
- 23.8%
- -41.5%
- -141.9%
- –
Growth
- –
- –
- −20.4%
- –
- +0.9%
Financial health
- -0.8×
- -0.01
- 1.3%
- –
- 1.09
- 1.09
- 0.00
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.05 | -0.54 | +90.7% |
| Mar 25, 2026 | -0.05 | -0.54 | +90.3% |
| Nov 12, 2025 | -0.05 | – | – |
| Aug 13, 2025 | -0.04 | – | – |
| May 12, 2025 | -0.06 | – | – |
| Mar 27, 2025 | 0.08 | – | – |
| Aug 9, 2024 | -0.09 | – | – |
| Apr 29, 2024 | -0.11 | – | – |
News
BeyondSpring GAAP EPS of -$0.02Seeking Alpha · Aug 17, 2026The newest story we have is from Aug 17, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
46No pass
Benjamin Graham
12No pass
Philip Fisher
41No pass
Peter Lynch
–Not enough data
Joel Greenblatt
2No pass
Charlie Munger
44No pass
Terry Smith
47No pass
Questions about BeyondSpring
Is BeyondSpring a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the BeyondSpring AI analysis
What does BeyondSpring do?
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. It is in Biotechnology.
Does BeyondSpring pay a dividend?
No. BeyondSpring does not pay a dividend at the moment.
Is BeyondSpring stock halal?
Questionable. BeyondSpring sits in a grey zone: its cash and confirmed interest-bearing investments are 31% of its market value, between 30% and 33%. How we check
How has BeyondSpring stock done over the past year?
Down 68.5% over the past twelve months, to $0.62. It traded between $0.43 and $2.35 and is 73.7% below its high.
Who are BeyondSpring's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with BeyondSpring's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.